en
svPress releases
Regulatory press release 2023-11-08
Interim Report Third Quarter 2023
Press release 2023-10-26
Xspray Publication Demonstrates High Concomitant PPI and TKI Use in CML Resulting in Risk of Increased Mortality Which May be Mitigated by DASYNOC™
Regulatory press release 2023-10-24
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2024
Press release 2023-09-15
Xspray Pharma appoints Chief Commercial Officer to drive upcoming Dasynoc™ US product commercialization
Regulatory press release 2023-09-11
Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Litigation, Paving Way for Early Market Launch
Regulatory press release 2023-08-02
Interim Report Second Quarter 2023
Regulatory press release 2023-07-31
New number of shares and votes in Xspray Pharma
Regulatory press release 2023-07-11
Xspray Pharma receives request for additional information concerning Dasynoc from FDA
Regulatory press release 2023-06-27
Xspray raises approximately SEK 251 million through a rights issue
Regulatory press release 2023-05-30